INDIA & LOS ANGELES, CA—When we look at where ayurveda can meet real global needs, ashwagandha and shatavari are the two botanicals that clearly stand out.

When natural products raw material supplier Ixoreal Biomed launched its flagship KSM-66 Ashwagandha ingredient (known as “King of Ayurvedic Herbs”), the company felt it natural that its second ingredient would its counterpart Shatavari (the “Queen of Herbs”) revered in ayurveda for women’s health. SRI-81 Shatavari will be launched at SupplySide Global, which will be held at the Mandalay Bay Convention Center in Las Vegas, NV from Oct. 27-30.

Shatavari is called ‘Queen of the Herbs’ for good reason. It has been linked for centuries with women’s healthy by supporting hormonal balance, reproductive health, lactation, menopause support and overall well-being.

“Yet, despite these quintessential benefits for women, Shatavari has been largely overlooked in the global nutraceutical space. With SRI-81 Shatavari, we’re bringing the same scientific rigor, standardization, and credibility to Shatavari that we pioneered with KSM-66 Ashwagandha. For us, it is the right herb at the right moment: rooted in heritage, but with huge relevance for today’s consumers,” said an Ixoreal spokesperson.

The U.S. market will be one of the primary entry points given the scale, openness to innovation and readiness to embrace an ayurvedic ingredient that’s backed by science. Ixoreal’s vision is to establish SRI-81 Shatavari as the gold-standard shatavari extract across the world.

Just like KSM-66, the approach is to build a strong foundation of science, quality, sustainability and credibility that resonates worldwide. Long term, Shatavari has the potential to play the same role in women’s health that Ashwagandha now plays in stress and vitality, something that belongs in every household everywhere.

Ixoreal built on the same model that made KSM-66 one of the most trusted ingredient brands worldwide: complete control over the supply chain. Shatavari is cultivated from its own certified organic farms with a strong focus on soil health, traceability and sustainable practices. It’s not just about consistency and quality; it’s also about doing right by the farmers and the land.

SRI-81 Shatavari is backed by 10 clinical studies and focuses on key areas of women’s health such as perimenopause, menopause, sexual function, lactation support and hormonal balance. Ixoreal is committed to proving the science, not just relying on tradition. This is the same philosophy that guided KSM-66 Ashwagandha.

So far, the work and research, combined with the suggestions from traditional texts, puts the effective dose of SRI-81 Shatavari at 300 mg. Ixoreal wants to keep everything practical for formulators, but also make sure the dose delivers results.

After the launch of SRI-81, there will likely be many other shatavari extracts entering the market that will about extremely low dosages of 50 mg and 100 mg, and extremely high concentrations of up to 20 percent total shatavarins. What is important is the most optimum levels of bioactives and most optimal dosage, which in the case of SRI-81 Shatavari, is backed by years of research and trials.

“KSM-66 taught us that if you invest in the right science, quality and storytelling, you can take an Ayurvedic herb and make it part of everyday life for people around the world. With SRI-81, we’re following the same playbook: vertical integration, clinical research, sustainability, transparency and education. But it’s also about the bigger lesson, we learned that when you respect the tradition and deliver real science, you don’t just launch a product, you help create a category. That’s exactly what we hope to do with SRI-81 Shatavari,” said an Ixoreal spokesperson.

www.ksm66ashwagandhaa.com

India Office:
Plot No-1057-F2, PBN Center, Road No. 45
Jubilee Hills, Hyderabad-500033 Telangana, India
+91-40-2355-4386

U.S. Office:
1039 Selby Ave
Los Angeles, CA 90024-3105
+1 (310) 424-5535
[email protected]